THE LARGEST BODY OF EVIDENCE1–21

Over 10 years of robust clinical evidence support the efficacy and
safety of ALECENSA across early- and late-stage ALK+ NSCLC1–19

A trusted treatment worldwide22

A trusted treatment worldwide22

 

Over 137,000 patients in 100+ countries

have been treated with ALECENSA22

 

 

 

Over 137,000 patients in 100+ countries

have been treated with ALECENSA22

 

 

Learn more

 

ABOUT ALECENSA 


DOSING AND ADMINISTRATION >

1L, first-line therapy; 2L, second-line therapy; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer.

 

1. Seto T, et al. Lancet Oncol 2013;14:590–298. 2. Ou SH, et al. J Clin Oncol 2016;34:661–668. 3. Barlesi F, et al. Ann Oncol 2016;27(Supplement 6):vi416–vi545. 4. Yang JCH, et al. Thorac Oncol 2017;12):1552–1560. 5. Shaw AT, et al. Lancet Oncol 2016;17:234–242. 6. Hida T, et al. Lancet 2017;390:29–39. 7. Nakagawa K, et al. Lung Cancer 2020;139:195–199. 8. Peters S, et al. N Engl J Med 2017;377:819–838. 9. Mok T, et al. Ann Oncol 2020;31:1056–1064. 10. Peters S, et al. Ann Oncol 2025. DOI: 10.1016/j.annonc.2025.09.018. 11. Novello S, et al. Annals Oncol 2018;29:1409–1416. 12. Wolf J, et al. ESMO Open 2022;7:100333. 13. Zhou C, et al. Lancet Respir Med 2019;7:437–446. 14. Zhou C, et al JTO Clin Res Rep 2024;5:100700. 15. Dziadziuszko R, et al. J Thorac Oncol 2021;16:2040–2050. 16. Gadgeel SM, et al. Ann Oncol 2023;34:S782–S783. 17. Kim DW, et al. JTO Clin Res Rep 2022;3:100367. 18. Wu YL, et al. N Engl J Med 2024;390:1265–1276. 19. Dziadziuszko R, et al. Updated results from the Phase III ALINA study of adjuvant alectinib vs chemotherapy in patients with early stage ALK+ non-small cell lung cancer (NSCLC). ESMO. 17–21 October 2025. Berlin, Germany.  20. Popat S, et al. HORIZON-01: A Phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). BTOG. 3–5 March 2025. Belfast, Ireland. 21. Arrieta O, et al. Nat Commun 2025;16:4553. 22. Roche. Data on file.

 

 

© 2025 F. Hoffmann-La Roche Ltd. M-XX-00021690; Date of preparation: December 2025 Legal Statement - Privacy Policy - Cookie Preferences